Literature DB >> 25917016

Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Steven D Rhodes1,2, Hao Yang2,3, Ruizhi Dong2,3, Keshav Menon2,3, Yongzheng He2,3, Zhaomin Li2,3, Shi Chen2,3, Karl W Staser2,3, Li Jiang2,3, Xiaohua Wu2,3, Xianlin Yang2,3, Xianghong Peng4, Khalid S Mohammad4, Theresa A Guise4, Mingjiang Xu2,3,5, Feng-Chun Yang1.   

Abstract

Although nullizygous loss of NF1 leads to myeloid malignancies, haploinsufficient loss of NF1 (Nf1) has been shown to contribute to osteopenia and osteoporosis which occurs in approximately 50% of neurofibromatosis type 1 (NF1) patients. Bone marrow mononuclear cells of haploinsufficient NF1 patients and Nf1(+/-) mice exhibit increased osteoclastogenesis and accelerated bone turnover; however, the culprit hematopoietic lineages responsible for perpetuating these osteolytic manifestations have yet to be elucidated. Here we demonstrate that conditional inactivation of a single Nf1 allele within the myeloid progenitor cell population (Nf1-LysM) is necessary and sufficient to promote multiple osteoclast gains-in-function, resulting in enhanced osteoclastogenesis and accelerated osteoclast bone lytic activity in response to proresorptive challenge in vivo. Surprisingly, mice conditionally Nf1 heterozygous in mature, terminally differentiated osteoclasts (Nf1-Ctsk) do not exhibit any of these skeletal phenotypes, indicating a critical requirement for Nf1 haploinsufficiency at a more primitive/progenitor stage of myeloid development in perpetuating osteolytic activity. We further identified p21Ras-dependent hyperphosphorylation of Pu.1 within the nucleus of Nf1 haploinsufficient myelomonocytic osteoclast precursors, providing a novel therapeutic target for the potential treatment of NF1 associated osteolytic manifestations.
© 2015 American Society for Bone and Mineral Research.

Entities:  

Keywords:  GENETIC ANIMAL MODELS < ANIMAL MODELS; OSTEOCLASTS < CELLS OF BONE; OSTEOPOROSIS < DISEASES AND DISORDERS OF/RELATED TO BONE

Mesh:

Substances:

Year:  2015        PMID: 25917016      PMCID: PMC5441523          DOI: 10.1002/jbmr.2538

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  52 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Phenotypic characterization of transgenic mice harboring Nf1+/- or Nf1-/- osteoclasts in otherwise Nf1+/+ background.

Authors:  Maria H Alanne; Elina Siljamäki; Sirkku Peltonen; Kalervo Väänänen; Jolene J Windle; Luis F Parada; Jorma A Määttä; Juha Peltonen
Journal:  J Cell Biochem       Date:  2012-06       Impact factor: 4.429

Review 3.  Roles of osteoclasts in the control of medullary hematopoietic niches.

Authors:  Claudine Blin-Wakkach; Matthieu Rouleau; Abdelilah Wakkach
Journal:  Arch Biochem Biophys       Date:  2014-07-03       Impact factor: 4.013

4.  Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation.

Authors:  Eetu Heervä; Maria H Alanne; Sirkku Peltonen; Tommi Kuorilehto; Teuvo Hentunen; Kalervo Väänänen; Juha Peltonen
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

5.  Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.

Authors:  Eetu Heervä; Laura Huilaja; Pekka Leinonen; Sirkku Peltonen; Juha Peltonen
Journal:  Calcif Tissue Int       Date:  2014-01-04       Impact factor: 4.333

6.  Bone mineral density in children and adolescents with neurofibromatosis type 1.

Authors:  David A Stevenson; Laurie J Moyer-Mileur; Mary Murray; Hillarie Slater; Xiaoming Sheng; John C Carey; Bukhosi Dube; David H Viskochil
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

7.  Transgenic mice that express Cre recombinase in osteoclasts.

Authors:  W S M Chiu; J F McManus; A J Notini; A I Cassady; J D Zajac; R A Davey
Journal:  Genesis       Date:  2004-07       Impact factor: 2.487

8.  Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).

Authors:  T Tucker; C Schnabel; M Hartmann; R E Friedrich; I Frieling; H-P Kruse; V-F Mautner; J M Friedman
Journal:  J Med Genet       Date:  2008-12-09       Impact factor: 6.318

9.  Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.

Authors:  Jincheng Yan; Shi Chen; Yingze Zhang; Xiaohong Li; Yan Li; Xiaohua Wu; Jin Yuan; Alexander G Robling; Reuben Kapur; Reuben Karpur; Rebecca J Chan; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2007-12-18       Impact factor: 6.150

10.  The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.

Authors:  Xiaohua Wu; Shi Chen; Yongzheng He; Steven D Rhodes; Khalid S Mohammad; Xiaohong Li; Xianlin Yang; Li Jiang; Grzegorz Nalepa; Paige Snider; Alexander G Robling; D Wade Clapp; Simon J Conway; Theresa A Guise; Feng-Chun Yang
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

View more
  2 in total

Review 1.  Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.

Authors:  Steven D Rhodes; Feng-Chun Yang
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

2.  Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC).

Authors:  Yajing Chu; Zhigang Zhao; David Wayne Sant; Ganqian Zhu; Sarah M Greenblatt; Lin Liu; Jinhuan Wang; Zeng Cao; Jeanette Cheng Tho; Shi Chen; Xiaochen Liu; Peng Zhang; Jaroslaw P Maciejewski; Stephen Nimer; Gaofeng Wang; Weiping Yuan; Feng-Chun Yang; Mingjiang Xu
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-06-13       Impact factor: 7.691

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.